CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Clemedi AG is developing a platform for rapid diagnosis of drug-resistant infections, particularly multi-drug-resistant tuberculosis. The platform uses DNA analysis and machine learning to provide personalized antibiotic therapy recommendations within 24-48 hours.
Company:
Clemedi AG is a Swiss SME, founded in 2019 as a spin-off from the University of Zurich, with the aim to develop in vitro diagnostic (IVD) tests for antibiotic resistance and susceptibility in infectious diseases.
The vision of Clemedi is to support the global battle against antibiotic resistance by developing IVDs that will allow personalized prescription of antibiotics.Need to address:
Antimicrobial resistant infections will be among the world’s leading causes of death by 2050.
Multi-d…
CLEMEDI AG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
